Sabin株灭活脊髓灰质炎疫苗II期随机剂量探索试验的安全性与免疫原性
该随机双盲II期试验比较了2月龄婴儿接种高、中、低D抗原含量sIPV(A、B、C组)与常规IPV(D组)及sIPV(CAMS,E组)三剂后的免疫原性与安全性。三剂后各组各型血清转化率均接近或达100%,中剂量组(B组)各型GMT分别为4635、342、2218。A组肿胀(4.2%,P=0.0075)和发热(58.3%,P=0.0188)频率显著高于其他组,中剂量D抗原被认为是III期临床的首选。
要点
- 三剂后A-E组1型血清转化率分别为100%、98.2%、100%、100%、100%。
- A-E组2型血清转化率分别为99.1%、100%、98.1%、100%、97.1%。
- A-E组3型血清转化率分别为100%、100%、100%、100%、99.0%。
核心结论
- 试验用sIPV总体显示良好的安全性和免疫原性,中剂量D抗原因对各血清型高免疫原性和良好耐受性成为III期临床首选。
研究设计与样本
- 随机双盲临床试验,纳入2月龄(60-90天)婴儿,比较五种疫苗接种方案:A、B、C组分别接种高、中、低D抗原含量sIPV三剂,D组接种常规IPV三剂,E组接种sIPV(CAMS)三剂,均按0、1、2月程序。
主要发现
- 三剂后A-E组1型血清转化率分别为100%、98.2%、100%、100%、100%。
- A-E组2型血清转化率分别为99.1%、100%、98.1%、100%、97.1%。
- A-E组3型血清转化率分别为100%、100%、100%、100%、99.0%。
- A-E组所有型别血清阳性率(≥1:8)接近100%。
- 目标剂量组(B组)1-3型GMT分别为4635、342、2218。
关键数值与推荐
- 血清转化率:A-E组1型100%、98.2%、100%、100%、100%;2型99.1%、100%、98.1%、100%、97.1%;3型100%、100%、100%、100%、99.0%。
- 血清阳性率(≥1:8):A-E组所有型别接近100%。
- B组GMT:1型4635、2型342、3型2218。
- A组肿胀4.2%(P=0.0075)、发热58.3%(P=0.0188)显著高于其他组。
临床怎么用
- 中剂量D抗原sIPV因对各血清型高免疫原性和良好耐受性,被推荐为III期临床试验的首选剂量。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In order to completely eradicate polio caused by wild poliovirus infection as well as vaccine-associated paralytic polio (VAPP), Sabin inactivated poliovirus vaccine (sIPV) should be developed to meet the requirements for biosafety and affordable strategy in the developing countries. METHOD: A randomized, double-blinded clinical trial was conducted to compare the immunogenicity and safety among infants aged 2 months (60-90 days) receiving five different vaccination regimens: the test groups (A, B, and C) received three doses of sIPV with high, medium, and low D antigen content, respectively, on the month 0, 1, 2 schedule; two control groups (D and E) received three doses of conventional IPV (cIPV) or sIPV (CAMS), respectively, on the same schedule as that of test groups. Serum samples were collected immediately before the 1st dose and 30 days after the 3rd dose vaccination to assess the immunogenicity. Adverse events occurring within 30 days after each dose were collected to assess the safety. RESULTS: After three doses, seroconversion rates in groups A-E were 100%, 98.2%, 100%, 100%, and 100%, respectively, for type 1; 99.1%, 100%, 98.1%, 100%, and 97.1%, respectively, for type 2; and 100%, 100%, 100%, 100%, and 99.0%, respectively, for type 3. The seropositive rates (≥1:8) of groups A-E for all types were nearly 100%. The GMTs in the target dose group (group B) were 4635, 342, and 2218 for type 1-3, respectively. The most common injection-site and systemic adverse reactions were swelling and fever respectively. The swelling (4.2%, P = 0.0075) and fever (58.3%, P = 0.0188) frequency of group A were statistically significantly higher than any other groups. CONCLUSION: The test sIPV generally demonstrated good safety and immunogenicity. The medium-D antigen dose would be a preferred choice for the further phase III clinical trial in consideration of its high immunogenicity for all serotypes and the satisfying tolerance. CLINICAL TRIALS REGISTRATION: NCT02985320.
引用
- Chu K, Ying Z, Wang L, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine. 2018. PMID: 30249424. doi:10.1016/j.vaccine.2018.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。